Cargando…
Probiotics for the treatment of depression and its comorbidities: A systemic review
Depression is one of the most common psychiatric conditions, characterized by significant and persistent depressed mood and diminished interest, and often coexists with various comorbidities. The underlying mechanism of depression remain elusive, evidenced by the lack of an appreciate therapy. Recen...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149938/ https://www.ncbi.nlm.nih.gov/pubmed/37139495 http://dx.doi.org/10.3389/fcimb.2023.1167116 |
_version_ | 1785035255064821760 |
---|---|
author | Gao, Jie Zhao, Longyou Cheng, Yiwen Lei, Wenhui Wang, Yu Liu, Xia Zheng, Nengneng Shao, Li Chen, Xulei Sun, Yilai Ling, Zongxin Xu, Weijie |
author_facet | Gao, Jie Zhao, Longyou Cheng, Yiwen Lei, Wenhui Wang, Yu Liu, Xia Zheng, Nengneng Shao, Li Chen, Xulei Sun, Yilai Ling, Zongxin Xu, Weijie |
author_sort | Gao, Jie |
collection | PubMed |
description | Depression is one of the most common psychiatric conditions, characterized by significant and persistent depressed mood and diminished interest, and often coexists with various comorbidities. The underlying mechanism of depression remain elusive, evidenced by the lack of an appreciate therapy. Recent abundant clinical trials and animal studies support the new notion that the gut microbiota has emerged as a novel actor in the pathophysiology of depression, which partakes in bidirectional communication between the gut and the brain through the neuroendocrine, nervous, and immune signaling pathways, collectively known as the microbiota-gut-brain (MGB) axis. Alterations in the gut microbiota can trigger the changes in neurotransmitters, neuroinflammation, and behaviors. With the transition of human microbiome research from studying associations to investigating mechanistic causality, the MGB axis has emerged as a novel therapeutic target in depression and its comorbidities. These novel insights have fueled idea that targeting on the gut microbiota may open new windows for efficient treatment of depression and its comorbidities. Probiotics, live beneficial microorganisms, can be used to modulate gut dysbiosis into a new eubiosis and modify the occurrence and development of depression and its comorbidities. In present review, we summarize recent findings regarding the MGB axis in depression and discuss the potential therapeutic effects of probiotics on depression and its comorbidities. |
format | Online Article Text |
id | pubmed-10149938 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101499382023-05-02 Probiotics for the treatment of depression and its comorbidities: A systemic review Gao, Jie Zhao, Longyou Cheng, Yiwen Lei, Wenhui Wang, Yu Liu, Xia Zheng, Nengneng Shao, Li Chen, Xulei Sun, Yilai Ling, Zongxin Xu, Weijie Front Cell Infect Microbiol Cellular and Infection Microbiology Depression is one of the most common psychiatric conditions, characterized by significant and persistent depressed mood and diminished interest, and often coexists with various comorbidities. The underlying mechanism of depression remain elusive, evidenced by the lack of an appreciate therapy. Recent abundant clinical trials and animal studies support the new notion that the gut microbiota has emerged as a novel actor in the pathophysiology of depression, which partakes in bidirectional communication between the gut and the brain through the neuroendocrine, nervous, and immune signaling pathways, collectively known as the microbiota-gut-brain (MGB) axis. Alterations in the gut microbiota can trigger the changes in neurotransmitters, neuroinflammation, and behaviors. With the transition of human microbiome research from studying associations to investigating mechanistic causality, the MGB axis has emerged as a novel therapeutic target in depression and its comorbidities. These novel insights have fueled idea that targeting on the gut microbiota may open new windows for efficient treatment of depression and its comorbidities. Probiotics, live beneficial microorganisms, can be used to modulate gut dysbiosis into a new eubiosis and modify the occurrence and development of depression and its comorbidities. In present review, we summarize recent findings regarding the MGB axis in depression and discuss the potential therapeutic effects of probiotics on depression and its comorbidities. Frontiers Media S.A. 2023-04-17 /pmc/articles/PMC10149938/ /pubmed/37139495 http://dx.doi.org/10.3389/fcimb.2023.1167116 Text en Copyright © 2023 Gao, Zhao, Cheng, Lei, Wang, Liu, Zheng, Shao, Chen, Sun, Ling and Xu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular and Infection Microbiology Gao, Jie Zhao, Longyou Cheng, Yiwen Lei, Wenhui Wang, Yu Liu, Xia Zheng, Nengneng Shao, Li Chen, Xulei Sun, Yilai Ling, Zongxin Xu, Weijie Probiotics for the treatment of depression and its comorbidities: A systemic review |
title | Probiotics for the treatment of depression and its comorbidities: A systemic review |
title_full | Probiotics for the treatment of depression and its comorbidities: A systemic review |
title_fullStr | Probiotics for the treatment of depression and its comorbidities: A systemic review |
title_full_unstemmed | Probiotics for the treatment of depression and its comorbidities: A systemic review |
title_short | Probiotics for the treatment of depression and its comorbidities: A systemic review |
title_sort | probiotics for the treatment of depression and its comorbidities: a systemic review |
topic | Cellular and Infection Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149938/ https://www.ncbi.nlm.nih.gov/pubmed/37139495 http://dx.doi.org/10.3389/fcimb.2023.1167116 |
work_keys_str_mv | AT gaojie probioticsforthetreatmentofdepressionanditscomorbiditiesasystemicreview AT zhaolongyou probioticsforthetreatmentofdepressionanditscomorbiditiesasystemicreview AT chengyiwen probioticsforthetreatmentofdepressionanditscomorbiditiesasystemicreview AT leiwenhui probioticsforthetreatmentofdepressionanditscomorbiditiesasystemicreview AT wangyu probioticsforthetreatmentofdepressionanditscomorbiditiesasystemicreview AT liuxia probioticsforthetreatmentofdepressionanditscomorbiditiesasystemicreview AT zhengnengneng probioticsforthetreatmentofdepressionanditscomorbiditiesasystemicreview AT shaoli probioticsforthetreatmentofdepressionanditscomorbiditiesasystemicreview AT chenxulei probioticsforthetreatmentofdepressionanditscomorbiditiesasystemicreview AT sunyilai probioticsforthetreatmentofdepressionanditscomorbiditiesasystemicreview AT lingzongxin probioticsforthetreatmentofdepressionanditscomorbiditiesasystemicreview AT xuweijie probioticsforthetreatmentofdepressionanditscomorbiditiesasystemicreview |